Supernus And Indivior Merger: There May Be Some Skepticism, But I Have Faith In This Deal
· seekingalpha.com
Supernus Pharmaceuticals will merge with Indivior in a tax-free all-stock deal, creating a CNS-focused company with $2.2bn pro forma revenues. Read more here.
If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and ...